• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Vytorin Study Causes Media Stir, but Are the Concerns Justified?

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-01-23-2008
Volume 0
Issue 0

Unlike Vioxx, Vytorin works exactly as explained in its now-famous food-and-family ads. So why are people up in arms against the drug? Experts ponder what went wrong.

Merck and Schering-Plough's announcement last week that Vytorin did not show any evidence of reducing fatty plaque buildup in veins and arteries stirred up a lot of complaints from industry pundits who felt that the public was misled by pharma.

There's only one hitch: The two pharma companies never stated that the drug, a cholesterol-lowering combination of Zocor and Zetia, had an effect on plaque.

Related Videos
Related Content